Asset Details
Do you wish to reserve the book?
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐VTE/NEJ037 Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐VTE/NEJ037 Study
Do you wish to request the book?
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐VTE/NEJ037 Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐VTE/NEJ037 Study
2025
Overview
ABSTRACT
Background
Cancer‐associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of cancer‐associated arterial thromboembolism (ATE) and the efficacy of DOACs remain unclear.
Objectives
To evaluate the risk factors and the clinical activity of edoxaban (EDO) for the prevention of ATE in patients with advanced lung cancer.
Methods
From the prospective Rising‐VTE/NEJ037 study which investigated VTE in newly diagnosed advanced lung cancer, we investigated the incidence rate and the risk factors of ATE as secondary endpoints.
Results
A total of 1008 patients were screened for VTE at study baseline and were followed up for 2 years. Excluding patients with a contraindication to DOACs, those with VTE were treated with EDO. ATE events were identified in 41 patients (4.1%). The most common location for ATE was cerebral infarction (N = 31, 75.6%), followed by myocardial infarction (N = 4, 9.8%). Multivariate analysis determined the incidence of VTE, D‐dimer, a comorbidity of atrial fibrillation, and four other factors as independent risk factors of ATE. For VTE (+) patients, the incidence rate of ATE was 15.9% for the EDO administration (+) patients, compared with 11.1% for the EDO administration (−) patients (p = 0.626).
Conclusions
The incidence rate of ATE was 4.1% over 2‐year follow‐up in advanced lung cancer patients. VTE was further identified as an independent risk factor for ATE, while intervention with DOACs was seen as less effective for the prevention of ATE in advanced lung cancer patients with VTE.
Trial Registration
This trial was registered in the Japan Registry of Clinical Trials (jRCTs061180025)
The incidence rate of arterial thromboembolism (ATE) was 4.1% over a 2‐year follow‐up in advanced lung cancer patients. Venous thromboembolism (VTE) was further identified as an independent risk factor for ATE, while intervention with direct oral anticoagulants was seen as less effective for the prevention of ATE in advanced lung cancer patients with VTE.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Cancer
/ cancer‐associated thromboembolism
/ Diabetes
/ Factor Xa Inhibitors - therapeutic use
/ Female
/ Humans
/ Lung Neoplasms - complications
/ Lung Neoplasms - drug therapy
/ Lung Neoplasms - epidemiology
/ Male
/ Mutation
/ Patients
/ Stroke
/ Thromboembolism - epidemiology
/ Thromboembolism - prevention & control
/ Venous Thromboembolism - epidemiology
